Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1Breast 1

Conditions

Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Carcinoma, Transitional Cell 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × erdafitinib × Genitourinary × Clear all
NCT05567185 2026-06-05

TAR-210

Janssen Pharmaceutical K.K.

Phase 1 Active not recruiting
5 enrolled
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡